Lysozyme amyloid related amyloidosis: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{SK}} ==Overview== ==Historical Perspective== ==Classification== ==Pathophysiology== ==Causes== ==Epidemiology and Demographics==..." |
Homa Najafi (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Homa}} | ||
{{SK}} | {{SK}} | ||
Revision as of 17:06, 5 November 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Synonyms and keywords:
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
References
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief:
Synonyms and keywords: